Prothrombin is a vitamin K-dependent blood coagulation protein that undergoes posttranslational y-carboxylation and propeptide cleavage during biosynthesis. The propeptide contains the y-carboxylation recognition site that directs y-carboxylation. To identify the intracellular sites of carboxylation and propeptide cleavage, we monitored the synthesis of prothrombin in Chinese hamster ovary cells stably transfected with the prothrombin cDNA by immunofluorescent staining. The vitamin K-dependent carboxylase was located in the endoplasmic reticulum and Golgi complex. Antibodies specific to prothrombin processing intermediates were used for immunocytolocalization. Anti-des-y-carboxyprothrombin antibodies stained only the endoplasmic reticulum whereas antiproprothrombin antibodies (specific ROTHROMBIN, a plasma glycoprotein, is a component P of the blood coagulation process and is the zymogen of the serine protease thrombin.' The synthesis of this protein requires vitamin K, and as such has been a prototype for the study of the calcium-binding proteins that contain ycarboxyglutamic acid. Prothrombin is synthesized in the liver, along with the other vitamin K-dependent blood clotting proteins. The prothrombin cDNA encodes a multidomain protein that includes a signal peptide, a propeptide, a domain rich in y-carboxyglutamic acid (Gla), a short aromatic amino acid stack domain, two kringle domains, and the serine protease domain.' The N-terminus includes 10 ycarboxyglutamic acid residues at residues 6, 7, 14, 16, 20, 21, 25, 26, 29, and 32 in human prothrombin. The x-ray crystal structure of the N-terminal third of bovine prothrombin has shown that many of these y-carboxyglutamic acid residues coordinate internal calcium ions, and thus stabilize the phospholipid binding structure of the Gla d0main.l
carboxylation recognition site.' The propeptides of the homologous vitamin K-dependent proteins share sequence similarity in that the carboxylation recognition site and the propeptide cleavage site are conserved! The propeptide is an amphipathic a helix, with the carboxylation recognition site located just N-terminal to the helix.7 This recognition element directs carboxylation' and mediates the binding of the propeptide in the prozymogen to the vitamin K-dependent carboxylase.* The model that has been proposed for the biosynthesis of the vitamin K-dependent proteins, including prothrombin and factor IX, is that the uncarboxylated precursor or prozymogen is first carboxylated.' The fully carboxylated prozymogen is then processed proteolytically by a propeptidase, furin, to remove the propeptide before secretion of the mature protein into the plasma." We have recently isolated and characterized fully carboxylated profactor M and found that, in contrast to factor IX, it does not bind to membrane surfaces in the presence of calcium ions?
The vitamin K-dependent carboxylase is a microsomal membrane protein that catalyzes the conversion of glutamic acid residues to y-carboxyglutamic acid residues. The cDNA for the propeptide) and antiprothrombin:Mg(lI) antibodies (which bind the carboxylated forms of proprothrombin and prothrombin) stained both the endoplasmic reticulum and the Golgi complex. Antiprothrombin:Ca(lI)-specific antibodies (which bind only to the carboxylated form of prothrombin lacking the propeptide) stained only the Golgi complex and secretory vesicles, and colocalired with antimannosidase II and anti-p200 in the juxtanuclear Golgi complex. These resutts indicate that uncarboxylated proprothrombin undergoes complete y-carboxylation in the endoplasmic reticulum and that y-carboxylation precedes propeptide cleavage during prothrombin biosynthesis.
0 1996 by The American Society of Hematology.
of the human" and the bovine'' y-carboxylase encodes a single-chain polypeptide composed of 758 amino acids. The active site responsible for glutamate binding and catalysis as well as the complementary site for the propeptide carboxylation recognition site are located in the N-terminal one third of the p r~t e i n . '~. '~ Vitamin K epoxidase activity is also catalyzed by the carbo~ylase'~; a C-terminal region of this enzyme is required for this activity.I6 Furin is a membraneassociated, calcium-dependent serine endopeptidase homologous to the bacterial subtilisins." This enzyme catalyzes precursor processing at Arg-X-Lys/Arg-Argl, a motif in proprothrombin (Arg-Val-Arg-Arg) at residues -4 to -1. Furin, synthesized as a zymogen and autoproteolytically activated," is concentrated in the trans Golgi network."
To further understand the intracellular posttranslational processing that accompanies the synthesis of the vitamin Kdependent proteins, we have examined the biosynthesis of human prothrombin expressed in heterologous Chinese hamster ovary (CHO) cells. These cells synthesize biologically active prothrombin that is fully carboxylated when the cells are grown in the presence of vitamin K." Using a panel of antibodies directed against various biosynthetic intermediates of we have studied prothrombin biosynthesis using immunofluorescence subcellular localization techniques. An antibody against the propeptide recognizes proprothrombin but not prothrombin; an antibody against abnormal (des-y-carboxy) prothrombin recognizes uncarboxylated prothrombin and uncarboxylated proprothrombin.*' The conformation-specific antibody antiprothrombin:Mg(II) recognizes fully carboxylated prothrombin regardless of the presence or absence of the propeptide.' The conformation-specific antiprothrombin:Ca(II)-specific antibodies bind only to fully carboxylated prothrombin in which the propeptide was cleaved. We conclude that the y-carboxylase resides in both the endoplasmic reticulum and the Golgi complex, but carboxylation is completed in the endoplasmic reticulum. Complete y-carboxylation precedes propeptide cleavage during prothrombin biosynthesis.
EXPERIMENTAL METHODS
Antibodies. The preparation of the immunoaffinity-purified conformation-specific antibodies, antiprothrombin:Mg(II) and antiprothrombin:Ca(II)-specific, have been previously described." Anti-abnormal prothrombin antibodies were prepared in rabbits using purified des-y-carboxy (abnormal) prothrombin as previously described. ** Antipropeptide antibodies to the prothrombin propeptide were prepared by the identical methods used to prepare anti-factor IX propeptide antibodiesz4 A synthetic peptide, KGGHVFLAPQQARSL-LQRVRR, representing residues -18 to -1 of prothrombin with an additional N-terminal tripeptide KGG for purposes of chemical linking, was synthesized on an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, CA). After purification, the sequence of the peptide was verified by automated Edman degradation using an Applied Biosystems 470A Protein Sequencer. The peptide was coupled to bovine serum albumin (BSA) using glutaraldehyde. The proprothrombin propeptide (150 pL; S mmol/ L), dissolved in phosphate-buffered saline (PBS; SO mmoVL phosphate, pH 7.41140 mmoVL NaC1) was mixed with 500 pL of 0.05 mmol/L BSA dissolved in PBS, and 350 pL of PBS was added. Glutaraldehyde ( 1 mL; 2.5 mmol/L; Sigma, St Louis, MO) was added dropwise to the peptide:BSA solution and stirred for 2 hours at room temperature. The final molar ratio of peptide:BSA:glutaraldehyde was 30:l:lOO. The peptide conjugate was dialyzed against PBS and stored at -20°C. A New Zealand White rabbit was immunized subcutaneously with 500 pg of the peptide:BSA conjugate in Freund's complete adjuvant ( I mL). The rabbit subsequently received monthly injections of 200 pg of the peptide:BSA conjugate in Freund's incomplete adjuvant ( I mL). Antiserum was prepared 10 to 14 days after each immunization. Antiprothrombin propeptide antibodies were purified by immunoaffinity chromatography using the synthetic propeptide or BSA linked to cyanogen bromide-activated Sepharose 4B (Sigma). Approximately 15 mL of antiserum was applied to a BSA-Sepharose column (7.5 mg BSA/mL Sepharose; 1 X 5 cm column) at 23°C to remove anti-BSA antibodies.
Antibodies that failed to bind were applied to a propeptide-Sepharose column (6 mg of propeptide/mL of Sepharose 4B; I X 5 cm column).
Bound antibody was eluted with 4 moVL guanidine HC1, and the guanidine eluate immediately dialyzed against Tris-buffered saline (TBS; 10 mmol/L Tris-HC1, pH 7.4/140 mmoVL NaCI) at 4°C.
Anticarboxylase antibodies directed against bovine carboxylase residues 86-99 and residues 661-675 were prepared as described.I2.l3 Antimannosidase I1 antibodiesz5 were the gift of Drs Marilyn G. Farquhar (University of California, San Diego) and Kelley Moremen (University of Georgia, Athens). A monoclonal antibody (MoAb), AD7, directed against the p200 protein associated with the Golgi complex," was the gift of Dr Brian Burke (Harvard Medical School, Boston, MA). Polyclonal anti-BiP (HSP78) antibodies were prepared in rabbits using a bovine liver carboxylase preparation in which BiP was the major component.' The IgG fraction of this antiserum was purified by affinity chromatography using protein A-Sepharose (Sigma).
Expression and pur$cation of proprothrombin/R-2D,R-IE. Mutant cDNA for proprothrombin/R-2D.R-lE was constructed using the site overlap extension method of the polymerase chain reaction (PCR).27 After gel purification and restriction digestion, the mutagenic DNA fragment was substituted for the wild-type fragment in pMT2-PT, a mammalian expression vector containing the cDNA for human prothrombin'" and the gene for dihydrofolate reductase. The entire region generated by the PCR was sequenced before transfection. A clonal population of dihydrofolate reductase-deficient CHO cells, CHO Dukx-B11/4,** was further selected for its ability to fully carboxylate prothrombin. Plasmid DNA was transfected into the cells using lipofectin (GIBCO-BRL Life Technologies, Gaithersburg, MD). Clones expressing prothrombin were detected by a filter hybridization assay using polyclonal antiprothrombin antibodies. CHO cells producing the highest levels of the mutant proprothrombin were introduced in 2,000 mL of medium into Nunc cell factories and allowed to grow for 7 days. The collected medium was concentrated in an Amicon Hollow Fiber Concentrator (model RA2000; Beverly, MA) and applied to an immunoaffinity column of polyclonal antiprothrombin antibodies. The column was washed with was applied to the cells on the coverslips, and the coverslips incubated for 45 minutes at 37°C. After washing in TBS, the cells were stained with rhodamine-labeled goat-antirabbit IgG (Pierce, Rockford, IL). After washing in TBS, the coverslips were mounted on glass slides with Airvol (Air Products, Allentown, PA). ImmunoHuorescence microscopy was performed on a Zeiss Axioscope fluorescence microscope at 6 3 0~ magnification (Zeiss, Thornwood, NY). Micrographs were prepared using Kodak T-400 black and white film (Eastman Kodak, Rochester, NY).
For double-label experiments, rabbit antiprothrombin:Ca(II)-specific antibodies (100 pg/mL) and AD7 (a murine antikp200 MoAb; ascites fluid I: 100 dilution) were mixed in dilution buffer (2% BSA, TBS, pH 7.4, 0.02% NaN,), applied to coverslips together, and incubated as described above. After washing with PIPES buffer (IS mmol/L PIPES, pH 7.4, 140 mmol/L NaC1, 1 mmol/L CaCI,), the coverslips were incubated with a mixture of rhodamine-conjugated goat-antimouse IgG (Pierce; diluted 1 :250 into dilution buffer) and fluorescein-conjugated donkey-antirabbit IgG (Pierce; diluted 1 : LOO in dilution buffer). In control experiments, either rabbit antiprothrombin:Ca(II) antibodies, AD7, or both were omitted to evaluate the specificity of staining with the second antibody. Samples were washed again in PIPES buffer and photographed at 630X magnification using a Zeiss Axioscope fluorescence microscope. Filter sets were used for excitation and visualization of fluorescein and rhoda-
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RESULTS
PuriJication and characterization of antibodies directed against the prothrombin propeptide. We generated a polyclonal antibody directed against the prothrombin propeptide A to examine the presence or absence of the propeptide in various intracellular prothrombin biosynthetic intermediates. This antibody was prepared in a rabbit using a synthetic peptide based on the sequence of proprothrombin (prom) (residues -18 to -1) that was coupled to BSA as a carrier protein. The antiprothrombin propeptide antibodies were purified from rabbit antiserum by sequential immunoaffinity chromatography. Antibody that failed to bind to BSA-Sepharose was applied to a propeptide-Sepharose column. The antibody that bound was eluted with 4 mol/L guanidine HCI and is referred to as anti-prow antibody.
Expression and characterization of proPT/R-ZD, R-1 E, Proprothrombin is efficiently processed in heterologous CHO cells2o and no proprothrombin can be detected after secretion. To obtain proprothrombin, CHO cells were transfected with a mutated form of prothrombin cDNA. These cells expressed the mutant form of prothrombin, proPT/R-2D,R-IE in which the arginine at -2 was mutated to an aspartic acid and the arginine at -1 that is adjacent to the propeptide cleavage site was mutated to a glutamic acid. Cells were grown in the presence of vitamin K to obtain proprothrombin that contained y-carboxyglutamic acid; cells were grown in the presence of warfarin, a vitamin K antagonist, to obtain proprothrombin that was deficient in y-carboxyglutamic acid. This mutant proprothrombin is similar to the naturally occurring mutant, factor IX Cambridge: in which factor IX circulates with an 18-residue propeptide Nterminal extension. ProPTR-2D,R-1 E, expressed in CHO cells in the presence of vitamin K or in the presence of warfarin, migrated as single bands after sodium dodecyl sulfate (SDS) gel electrophoresis (Fig 1A) . Direct y-carboxyglutamic acid analysis of the alkaline hydrolysate showed that proPT/R-2D,R-IE expressed in CHO cells in the presence of vitamin K contained 8.2 2 0.4 mol of y-carboxyglutamic acid per mol of protein; given the presence of minor contaminants, the prothrombin precursor is likely fully carboxylated. In contrast, proPTR-2D,R-1 E expressed in CHO cells in the presence of warfarin had no detectable ycarboxyglutamic acid. Upon Western blot analysis, both the carboxylated and the acarboxy form of prothrombinR-2D.R-IE as well as prothrombin stained with antiprothrombin:total antibodies (Fig IB) . However, the carboxylated and the acarboxy form of proPTR-2D,R-lE stained with anti-prow antibodies but prothrombin, lacking the propeptide, did not (Fig I E) . These results indicate that purified proprothrombin, in both its carboxylated and its uncarboxylated form, contains the propeptide and is reactive with anti-prow antibodies, in contrast to prothrombin. Although we have previously established the specificity of antibodies for various synthetic prothrombin intermediatesZ3 and parallel studies with factor IX antibodies allowed us to anticipate certain results for prothrombin~2J~2Y the absence of prior studies on proprothrombin necessitated evaluation of the interaction of antipropeptide antibodies, antiabnonnal prothrombin antibodies, antiprothrombin:Mg(II) antibodies, and antiprothrombin:Ca(II)-specific antibodies with prothrombin, proPTR-2D.R-1 E, des-y-carboxyprothrombin, and des-y-carboxyproPTR-2D,R-IE. The interaction of each antibody population was studied using a competition radioimmunoassay. Using 'ZSI-labeled proPTR-2D,R-1 E, the interaction of "'I-labeled proPTR-2D,R-1E with anti-prow antibodies was inhibited with proPTR-2D,R-lE and des-y-carboxyproPTR-2D,R-1 E but not prothrombin or des-y-carboxyprothrombin (Fig 2A) . Using "'I-labeled desy-carboxyprothrombin, the interaction of '2sI-labeled des-ycarboxyprothrombin with antiabnormal prothrombin antibodies was inhibited with des-y-carboxyprothrombin and, to a lesser extent, by des-y-carboxyproPTR-2D,R-1 E, but not prothrombin (Fig 2B) . ProPTR-2D.R-I E exhibited minimal reactivity with this antibody. The interaction of I2'I-
SpeciJcity of the antiprothrombin antibodies.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From labeled prothrombin with antiprothrombin:Mg(II) antibodies was inhibited with proPT/R-2D,R-IE and prothrombin but not des-y-carboxyprothrombin or des-y-carboxyproPTIR-2D,R-1 E (Fig 2C) . Using '2sI-labeled prothrombin, the interaction of '*'I-labeled prothrombin with antiprothrombin:Ca(lI)-specific antibodies was inhibited with prothrombin but proPT/R-2D,R-1 E, des-y-carboxyproPT/R-2D,R-1 E and des-y-carboxyprothrombin were unreactive with this antibody (Fig 2D) . These results indicate that anti-prow antibodies can be used to identify species that contain the propeptide, regardless of the state of carboxylation; that antiabnormal prothrombin antibodies can be used to identify des-y-carboxylated prothrombin species, regardless of the presence or absence of the propeptide; that antiprothrombin:Mg(II) antibodies recognize fully carboxylated prothrombin, regardless of the presence or absence of propeptide; that antiprothrombin:Ca(II) antibodies recognize fully carboxylated prothrombin only after the propeptide has been cleaved. Figure  3A shows the staining with anti-abnormal prothrombin antibodies of cells synthesizing prothrombin. These antibodies react with uncarboxylated or poorly carboxylated prothrombin species regardless of the presence or absence of the propeptide. The endoplasmic reticulum is stained specifically, whereas no staining of the Golgi complex can be observed. These results indicate that at the expression levels characteristic of these stably transfected CHO cells, y-carboxylation is an efficient process and appears to be completed in the endoplasmic reticulum.
Using antibovine carboxylase antibodies to stain the endogenous y-carboxylase of CHO cells, the endoplasmic reticulum and the Golgi complex represent the major sites of carboxylase (Fig 3C) . An endoplasmic reticulum marker, BiP (HSWS), stained with anti-BiP antibodies (Fig 3D) . These results indicate that the carboxylase resides in both the endoplasmic reticulum and the Golgi complex. However, carboxylation appears complete before transit of prothrombin from the endoplasmic reticulum to the Golgi complex because no des-y-carboxyprothrombin is observed in the Golgi complex.
Localization of propeptide-containing forms of prothrombin. Anti-prom antibodies reacted with proprothrombin regardless of the degree of y-carboxylation, but did not bind to prothrombin or des-y-carboxyprothrombin. As shown in Fig 3B, these antibodies stain both the endoplasmic reticulum and a component of the Golgi complex. The Golgi staining in CHO cells is perinuclear, but the particular region of the Golgi cannot be determined from these light micrographs. Because these antibodies do not bind to the free propeptide (J.A.B., unpublished results, December 1990), interpretation of these micrographs is not complicated by the localization of cleaved propeptide.
Localization of fully carboxylated forms of prothrombin. Antiprothrombin:Mg(II) antibodies bind to the fully carboxylated form of prothrombin regardless of the presence or absence of propeptide. These antibodies bind prothrombin only in the presence of metal ions. As shown in Fig 4A, antiprothrombin:Mg(II) antibodies are reactive with antigen in the endoplasmic reticulum and in the Golgi complex. When cells were fixed in the presence of EDTA, this binding was abolished (Fig 4B) . When CHO cells were cultured in Localization of acarboxy forms of prothrombin.
For medium containing warfarin to inhibit y-carboxylation, they failed to interact with antiprothrombin:Mg(II), even in the presence of calcium ions (data not shown). These results confirm that the interaction of these antibodies with prothrombin species requires y-carboxylation and that carboxylated prothrombin and carboxylated proprothrombin reside in both the endoplasmic reticulum and the Golgi complex.
Localization of fully carhmylatecl forms of protltrombin that lack the propeptide. Antiprothrombin:Ca(lI)-specific antibodies bind to the fully carboxylated form of prothrombin that lacks the propeptide. These antibodies bind prothrombin only in the presence of Ca(l1) ions and not other divalent metal ions. As shown in Fig 4C, antiprothrombin:Ca(ll)-specific antibodies are reactive with antigen in small granules within the cytoplasm as well as the Golgi complex. In the presence of EDTA, this binding was abolished ( Fig 4D) .
The juxtanuclear Golgi complex was localized using polyclonal antibodies to mannosidase I1 (Fig 5 ) ; mannosidase I1 is concentrated in the medial Golgi compartment,'" but this compartment and the trans Golgi network cannot be distinguished by immunofluorescence techniques.
To simultaneously localize prothrombin and the Golgi complex, we performed a double-label experiment to visualize carboxylated prothrombin, using antiprothrombin:Ca(II)-specific antibodies, and p200, a Golgi complex marker that colocalizes with mannosidase 11, using the MoAb AD7.l' p200 and carboxylated, propeptide-free prothrombin colocalized to the juxtanuclear Golgi complex and small cytoplasmic granules (Fig 6) . In control experiments, omission of AD7 resulted in the absence of a rhodamine signal, omission of antiprothrombin:Ca(II)-specific antibodies resulted in the absence of a fluorescein signal, and omission of both AD7 and antiprothrombin:Ca(II)-specific antibodies resulted in the absence of both rhodamine and fluorescein signals. Thus, mature prothrombin is located in the juxtanuclear Golgi complex and in small secretory granules.
DISCUSSION
The biosynthesis of the vitamin K-dependent proteins includes the posttranslational synthesis of y-carboxyglutamic acid. In this study we have identified the site of ycarboxylation and the site of propeptide cleavage by tracking immunochemically distinct forms of prothrombin through subcellular organelles. Using specific antibodies, we have been able to identify four chemically distinct prothrombin species: (1) uncarboxylated proprothrombin; (2) carboxylated proprothrombin; (3) uncarboxylated prothrombin; and (4) carboxylated prothrombin, the mature and biologically active species that circulates in blood. We and others have previously shown that the vitamin K-dependent proteins lack biologic activity if the propeptide is not cleaved4,q,3' or if carboxylation is not complete."." Such forms lack the ability to bind to membrane surfaces in the presence of calcium.
We demonstrate by direct immunofluorescence studies that the carboxylase resides in the endoplasmic reticulum and the Golgi complex. Previously, Carlisle and Suttie" had identified the endoplasmic reticulum as the site of carboxylase activity in studies based on the preparation and assay of For personal use only. on August 31, 2017. by guest www.bloodjournal.org From carboxylase in disrupted bovine liver cells. Wallin et aPS extended these studies by isolating preparations of both endoplasmic reticulum and the Golgi complex; both contained carboxylase activity. Because there remains uncertainty about the purity of these subcellular fractions, we used anticarboxylase antibodies in situ to perform immunocytochemical localization. These antibodies, including anti-carboxylase 86-99 and anti-carboxylase 661-675, were prepared against peptides based on the sequence of bovine carboxylBoth reagents showed identical staining patterns of ase. 12.13 both the endoplasmic reticulum and the Golgi complex. Thus, the vitamin K-dependent carboxylase is resident in both the endoplasmic reticulum and the Golgi complex. However, the apparent absence, within experimental limits, of uncarboxylated proprothrombin in the Golgi complex suggests that prothrombin is efficiently carboxylated in the endoplasmic reticulum before transit to the Golgi complex. The presence of carboxylase in the Golgi complex may be caused by membrane fusion and recycling of the carboxylase back to the endoplasmic reticulum, although the carboxylase lacks any of the known recognition elements that localize membrane proteins in the endoplasmic reticulum. ','* As previously described for factor IX? a synthetic propeptide based on the sequence of prothrombin was prepared and, after conjugation to albumin, was used as immunogen to generate rabbit antiprothrombin propeptide antibodies. After immunoaffinity purification, these antibodies were not reactive with prothrombin, but were reactive with the mutant proprothrombin, proPT/R-2D,R-lE, that we used as a model for the propeptide-containing prothrombin species. In contrast to the expression of recombinant factor IX CHO cells, where about 7% of the factor IX generated is profactor IX,9 CHO cells expressing prothrombin cleave the propeptide efficiently and no proprothrombin could be detected. Thus, we mutated residues -2 and -1 so that the propeptide cleavage site was altered and the propeptide remained attached to prothrombin. ProFT/R-2D,R-1E was nearly fully carboxylated and yielded a single band upon analysis by SDS gel electrophoresis. It was reactive with anti-prom antibodies, in contradistinction to prothrombin. Thus, the identification of proprothrombin within the cell by anti-prom antibodies is based on the expression of antigenic determinants in wildtype proprothrombin and proprothrombin with residues -1 and -2 altered.
This in situ analysis illustrates a pathway for the biosynthesis of the vitamin K-dependent proteins (Fig 7) . Prothrombin is synthesized in the endoplasmic reticulum as a precursor protein, including a propeptide N-terminal extension that contains the y-carboxylation recognition site.5 This precursor protein, proprothrombin, does not contain y-carboxyglutamic acid. This is consistent with carboxylation as a posttranslational process rather than a cotranslational process. Proprothrombin undergoes subsequent y-carboxylation. Although the carboxylase resides in both the endoplasmic reticulum and the Golgi complex, carboxylation is essentially complete before the protein leaves the endoplasmic reticulum. Thus, fully carboxylated proprothrombin exists within the cell, and is present in both the endoplasmic reticulum and in the Golgi complex. This result confirms our original hypothesis that the carboxylation recognition site on the propeptide directs y-carboxylation,5 and that propeptide cleavage must follow y-carboxylation. Fully carboxylated proprothrombin is further processed in the Golgi complex, with cleavage of the propeptide. Proprothrombin contains the furin concensus sequence. Because furin is known to reside in the trans Golgi network, and by immunofluorescence microscopy colocalizes to the Golgi complex with mannosidase II,I9 our observation of the conversion of proprothrombin to prothrombin in a Golgi compartment is consistent with the function and location of this enzyme." Prothrombin, fully carboxylated and lacking the propeptide, appears only in the Golgi complex and in secretory vesicles for constitutive secretion of this protein into the blood where it circulates as a plasma protein.
